Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Arctic Bioscience ASA is a biopharmaceutical company that specializes in the development and commercialization of biologically derived products for medical and nutrition industries. The primary focus of the company is on producing innovative therapies based on bioactive marine lipids, particularly omega-3 fatty acids, extracted from the Arctic. These compounds are essential in creating treatments that cater to neurological and autoimmune diseases, showcasing the company’s commitment to improving health outcomes through nature-sourced solutions. Arctic Bioscience ASA operates within the biotechnology sector, contributing to the growing field of marine-based bioproducts that aim to provide sustainable, eco-friendly health solutions. The company's dedication to research and development is central to its operations, emphasizing advancements in therapeutic applications and the global marine nutraceutical market. With its headquarters situated in Norway, Arctic Bioscience ASA leverages its geographical advantages to access high-quality marine resources, playing a crucial role in meeting the increasing demand for natural health products and contributing to a more sustainable future in the health sciences industry.
NOK 0.26
NOK 0.03 (-11.03%)
EOD Jul 1, 2026
The business is unprofitable at the operating level (-83.41% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 7.8% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -NOK 45M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 40M
▼ -7.8% YoY
Net Income (TTM)
-NOK 41M
▲ +14.4% YoY
Op. Margin
-83.41%
▲ +26.5pp YoY
ROIC
-11.03%
▲ +3.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 45M
▲ +52.8% YoY
Op. Cash Flow (TTM)
-NOK 37M
▲ +24.1% YoY
Net Debt
NOK 63M
Cash & Equiv.
NOK 218K
3Y CAGR: +5.4%
Continue Research
Arctic Bioscience ASA (ABS.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Arctic Bioscience ASA scores 26/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Arctic Bioscience ASA scores 26 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -83.4% operating margin and a -11.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ABS.XOSL's valuation and scores 26/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.